Phosphinic acid derivatives and their use as endothelin...

C - Chemistry – Metallurgy – 07 – F

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07F 9/30 (2006.01) A61K 31/66 (2006.01) C07F 9/547 (2006.01) C07F 9/572 (2006.01) C07F 9/6558 (2006.01)

Patent

CA 2191454

Phosphinic acid derivatives of structural formula (I) or a pharmaceutically acceptable salt thereof, wherein R is H, alkyl or alkanoyloxymethylene; R1, R2, R3 and R4 are H, alkyl, alkenyl, alkenylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxyalkyl, carboxyalkyl, thioalkyl, alkoxythioalkyl, aminoalkyl, alkylaminoalkyl, cycloalkyl-substituted alkyl or heterocycloalkyl; or R1 and R2 form a cycloalkyl ring of 3-8 members and R3 and R4 are as defined; or R3 and R4 form a cycloalkyl ring of 3-7 members and R1 and R2 are as defined; or R1 and R2 together, and R3 and R4 together, each form a cycloalkyl ring; R5 is -OR9 or -NHR9, wherein R9 is hydrogen or alkyl; n is 0 or 1; A1 is p-aminobenzoyl or p-aminobenzenesulfonyl, or A1 and R5 together form a radical of an .alpha.-aminoacyl derivative; and R6 is phenylmethoxycarbonyl, arylcarbonyl, heteroarylcarbonyl or -A2-R7, wherein A2 is a divalent .alpha.-iminoacyl radical, and R7 is a substituent on the .alpha.-imino atom selected from H, R8OCO-, R8SO2- and R8NHCO-, wherein R8 is aryl, arylmethyl or (C1-C8)alkyl; are disclosed for use as endothelin converting enzyme inhibitors; also disclosed are a genus of novel compounds wherein R3 and R4 form a cycloalkyl ring, and pharmaceutical compositions comprising said novel compounds.

Cette invention concerne des dérivés d'acide phosphinique de formule (I) ou un sel pharmaceutiqement acceptable de ces derniers. Dans la formule R représente H, alkyle ou alcanoyloxyméthylène; R¿1?, R¿2?, R¿3? et R¿4? représentent H, alkyle, alcényle, alcénylalkyle, aryle, arylalkyle, hétéroaryle, hétéroarylalkyle, hydroxyalkyle, carboxyalkyle, thioalkyle, alcoxythioalkyle, aminoalkyle, alkylaminoalkyle, alkyle ou hétérocycloalkyle à substitution cycloalkyle; ou R¿1? et R¿2? forment un cycle cycloalkyle composé de 3 à 8 éléments et R¿3? et R¿4? sont tels que définis ci-avant; ou R¿3? et R¿4? forment un cycle cycloalkyle composé de 3 à 7 éléments et R¿1? et R¿2? sont tels que définis ci-avant; ou bien encore R¿1? et R¿2? ensemble, et R¿3? et R¿4? ensemble, forment chacun un cycle cycloalkyle; R¿5? représente -OR¿9? ou -NHR¿9?, R¿9? représentant hydrogène ou alkyle; n représente 0 ou 1; A¿1? représente p-aminobenzoyle ou p-aminobenzènesulfonyle, ou A¿1? et R¿5? forment ensemble un radical ou un dérivé .alpha.-aminoacyle; et R¿6? représente phénylméthoxycarbonyle, arylcarbonyle, hétéroarylcarbonyle ou -A¿2?-R¿7?, A¿2? représentant un radical .alpha.-iminoacyle bivalent, et R¿7? représentant un substituant situé sur l'atome .alpha.-imino sélectioné parmi H, R¿8?OCO-, R¿8?SO¿2?- et R¿8?NHCO-, R¿8? représentant aryle, arylméthyle ou alkyle (C¿1?-C¿8?). Ces dérivés d'acide phosphinique ou leurs sels pharmaceutiquement acceptables sont utilisés comme inhibiteurs de l'enzyme de conversion de l'endothéline. Cette invention concerne également un genre de nouveaux composés dans lesquels R?3¿ et R?4¿ forment un cycle cycloalkyle; ainsi que des compositions pharmaceutiques contenant lesdits nouveaux composés.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Phosphinic acid derivatives and their use as endothelin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phosphinic acid derivatives and their use as endothelin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphinic acid derivatives and their use as endothelin... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1682862

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.